The net sales of the Orion Group during 1-9/2000 were MEUR 702.2 (MEUR 671.6 during 1-9/1999), up 4.6%. Profit before extraordinary items and taxes was MEUR 100.6 (MEUR 113.2) and it declined by 11.2%. Earnings per share were EUR 0.99 (EUR 1.17) and shareholders' equity per share EUR 9.67 (EUR 9.58). The most significant achievements during 7-9/2000 were the marketing agreement with Novartis concerning the triple therapy being developed by Orion Pharma for Parkinson's Disease, and the marketing approval and launch of Simdax in Sweden for acute decompensated heart failure.
The presentation of the report can be downloaded from the following link:
The full report including tables can be downloaded from the following link: